Cargando…

Paraneoplastic acute fibrinous and organizing pneumonia from lymphoma completely responding to bendamustine‐rituximab

Acute fibrinous and organizing pneumonia (AFOP) is a rare histopathological pattern of lung injury characterized by prominent fibrin deposition in alveolar spaces. It may be idiopathic or associated with medications, connective tissue disease, infection, environmental exposures, transplantation, and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Crowhurst, Thomas, Giri, Pratyush, Smith, Caroline, Nguyen, Phan, Reynolds, Paul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Ltd 2020
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7644388/ https://www.ncbi.nlm.nih.gov/pubmed/33194206 http://dx.doi.org/10.1002/rcr2.681

Ejemplares similares

Bendamustine/rituximab: COVID-19 pneumonia: case report
Publicado: (2021)

Rituximab and Bendamustine (BR) Compared with Rituximab, Bendamustine, and Cytarabine (R-BAC) in Previously Untreated Elderly Patients with Mantle Cell Lymphoma
por: Bega, Giulia, et al.
Publicado: (2021)

Large B - Cell Lymphoma of the Leg – Unfavourable Course with Rituximab/Bendamustin
por: Wollina, Uwe, et al.
Publicado: (2019)

An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma
por: Alderuccio, Juan Pablo, et al.
Publicado: (2022)

Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma
por: Vacirca, Jeffrey L., et al.
Publicado: (2013)

Evidence of bendamustine plus rituximab for old and frail patients with aggressive B-cell lymphoma
por: Schalk, Enrico, et al.
Publicado: (2023)

Clinical impact of bendamustine exposure on lymphopenia risk after bendamustine and rituximab combination therapy for follicular lymphoma: a single-institute retrospective study
por: Yamasaki, Satoshi, et al.
Publicado: (2021)

Bendamustine/dexamethasone/rituximab: Cytomegalovirus reactivation : case report
Publicado: (2021)

Bendamustine/rituximab: Neutropenia, fever and inflammation: case report
Publicado: (2022)

Two rare cases of bronchus‐associated lymphoid tissue lymphoma successfully treated with rituximab‐bendamustine
por: Panitz, Nydia, et al.
Publicado: (2021)

Bendamustine plus rituximab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma
por: Murayama, Kayoko, et al.
Publicado: (2022)

Bendamustine or high-dose cytarabine-based induction with rituximab in transplant-eligible mantle cell lymphoma
por: Villa, Diego, et al.
Publicado: (2022)

Rituximab/bendamustine/cytarabine for transplant‐eligible patients with mantle cell lymphoma: A retrospective study
por: Shimizu, Yuki, et al.
Publicado: (2023)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Primary diffuse large B-cell lymphoma of the bone: bendamustine and rituximab are able to overcome resistant disease
por: Mondello, Patrizia, et al.
Publicado: (2014)

Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan
por: Lane, Michael A., et al.
Publicado: (2015)

Salvage chemotherapy with R-BAD (rituximab, bendamustine, cytarabine, and dexamethasone) for the treatment of relapsed primary CNS lymphoma
por: Cho, Min-Seok, et al.
Publicado: (2016)

An unusual case of primary hepatic lymphoma with dramatic but unsustained response to bendamustine plus rituximab and literature review
por: Liao, Sih-Han, et al.
Publicado: (2017)

Patients with marginal zone dural lymphoma successfully treated with rituximab and bendamustine: A report of two cases
por: Tsutsumi, Yutaka, et al.
Publicado: (2021)

Severe Liver Damage and Nonallergic Bronchitis with Eosinophilia in a Patient with Follicular Lymphoma Treated with Bendamustine plus Rituximab
por: Jo, Tatsuro, et al.
Publicado: (2014)

Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients
por: Castelli, Roberto, et al.
Publicado: (2016)

Isolated intracardiac recurrence of diffuse large B-cell lymphoma successfully treated with rituximab and bendamustine chemotherapy regimen
por: Chang, CH, et al.
Publicado: (2020)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Perforating Folliculitis Secondary to Bendamustine-Rituximab Chemotherapy: A Case Report
por: Monteiro, Rowan, et al.
Publicado: (2017)

Painful, plantar nodules in cutaneous macroglobulinosis: Successful treatment with rituximab and bendamustine
por: D'Acunto, Carmine, et al.
Publicado: (2020)

A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma
por: Nakamura, Nobuhiko, et al.
Publicado: (2022)

Paraneoplastic Seronegative Pauci-Immune Glomerulonephritis Associated with Lung Adenocarcinoma Responds to Rituximab: A Case Report
por: Kancharla, Pragnan, et al.
Publicado: (2018)

Bendamustine in the treatment of non-Hodgkin’s lymphomas
por: Hagemeister, Fredrick, et al.
Publicado: (2009)

Health-related quality of life and symptoms in patients with rituximab-refractory indolent non-Hodgkin lymphoma treated in the phase III GADOLIN study with obinutuzumab plus bendamustine versus bendamustine alone
por: Cheson, Bruce D., et al.
Publicado: (2016)

A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B‐cell lymphoma
por: Terui, Yasuhito, et al.
Publicado: (2021)

First-line Treatment With Bendamustine and Rituximab for Old and Frail Patients With Aggressive Lymphoma: Results of the B-R-ENDA Trial
por: Braulke, Friederike, et al.
Publicado: (2022)

Polatuzumab‐bendamustine‐rituximab as bridge to CD19‐directed CAR T cells in mantle cell lymphoma refractory to ibrutinib and venetoclax
por: Perriello, Vincenzo Maria, et al.
Publicado: (2023)

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
por: Gressin, Rémy, et al.
Publicado: (2019)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

A Fatal Breakthrough COVID-19 Case Following Bendamustine-Rituximab Therapy
por: Kamegai, Kohei, et al.
Publicado: (2022)

Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy
por: Boudreault, Katherine, et al.
Publicado: (2017)

Acute fibrinous and organizing pneumonia
por: Al-Khouzaie, Thamer H., et al.
Publicado: (2013)

Acute fibrinous and organizing pneumonia()
por: García-Huertas, Daniela, et al.
Publicado: (2022)

Severe CMV Infection after Chemo-Immunotherapy with Dose-Reduced Bendamustine and Rituximab in a Mantle Cell Lymphoma Old Patient
por: Magliano, Gabriele, et al.
Publicado: (2021)

Vincristine Sulfate Liposome Injection with Bendamustine and Rituximab as First-Line Therapy for B-Cell Lymphomas: A Phase I Study
por: Ollila, Thomas, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_n4op5r4e1dekngpl8fg9q5a5je